A multi-glycoprotein synergized recombinant virus system resolves the research dilemma of Epstein-Barr virus entry and facilitates the development of entry-specific drugs or vaccines
Highlights • A novel virus system rEBV-VSV was developed realizing efficient and native EBV entry via multi-synergetic glycoproteins with sensitive bioluminescence detection. • rEBV-VSV was especially competent for rapid and high-throughput entry-inhibition evaluation of drugs, antibodies, or sera and accurate study of EBV entry mechanisms via flexible mutations or recombination on rEBV-VSV. • Glycoprotein 42 (gp42) was found to mediate diverse functions of an important mutation L65A+L69A on glycoprotein H (gH) and also manipulated the efficacy of gH-targeted antibodies.